TELCOR Promotions - June 2026
Lincoln, NE – June 2026 TELCOR is proud to announce the of promotion Haley Wagner to Front-End Services Lead, RCS.
1 min read
On May 29, Medicare announced it would expand coverage for genomic sequence analysis panels in the treatment of hematolymphoid diseases.
The local coverage determination (LCD) “provides limited coverage for genomic sequence analysis panels under specific clinical circumstances.” Specifically, these multi-gene panel tests would be used for diagnosis, risk stratification, and treatment planning for patients with hematolymphoid diseases, including newly diagnosed or relapsed/refractory acute myelogenous leukemia, myelodysplastic syndromes with nondiagnostic assessments, and myeloproliferative neoplasms requiring risk stratification or disease monitoring.
The College of American Pathologists applauded the proposed updates in a 2024 letter, expressing support for the decision to broaden coverage. According to CAP, the policy aligns with the National Comprehensive Cancer Network guidelines and the World Health Organization classifications.
The revision is effective for services performed on or after July 13, 2025.
Sources:
https://www.cap.org/advocacy/latest-news-and-practice-data/june-10-2025#story5
Key Revisions Finalized for Federal IDR Processes Under No Surprises Act
The Departments of Health and Human Services, Labor, and Treasury and the Office of Personnel Management released a final rule May 28 to improve the...
Stay Compliant with CMS and the New ABN Requirements
The Centers for Medicare & Medicaid Services (CMS) has issued an updated version of the Advance Beneficiary Notice of Noncoverage (ABN).